Literature DB >> 7478622

Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy.

A R Clarke1, M C Cummings, D J Harrison.   

Abstract

Murine strains which bear constitutive inactivating mutations of either the APC or the p53 tumor suppressor genes are characterised by spontaneous tumors. APC mutated (Min) mice develop large and small bowel adenomas, a small proportion of which, in time, become malignant. p53 deficient mice develop predominantly lymphoma and sarcoma. By interbreeding these strains we have shown that there is co-operativity between these mutations, leading to a shift in phenotype. Most notably, this was characterised by a range of abnormalities of the exocrine pancreas in 83% of animals heterozygous for the APC mutation and constitutively null for functional p53. Dysplasia and preneoplastic foci were seen in 61% of these animals and pancreatic acinar cell adenocarcinoma in 22%. Analysis of these tumors showed them to have lost the remaining wild-type copy of APC. Similar loss of APC was not associated with the development of other extra-intestinal tumors. Surprisingly, given the proposed role for loss of function mutations of the p53 gene in the development of human colorectal cancer, we have found no evidence for either an increase in the rate of adenoma formation in APC +/-, p53 -/- animals, or an increased rate of progression to malignancy compared with APC +/- p53 +/+ mice. These findings highlight striking tissue-specific differences in the tumor suppressor effects of p53.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478622

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

Review 1.  Transgenic models of pancreatic cancer.

Authors:  Andrew M Lowy
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 2.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

3.  Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin.

Authors:  C L Wilson; K J Heppner; P A Labosky; B L Hogan; L M Matrisian
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease.

Authors:  M Wagner; F R Greten; C K Weber; S Koschnick; T Mattfeldt; W Deppert; H Kern; G Adler; R M Schmid
Journal:  Genes Dev       Date:  2001-02-01       Impact factor: 11.361

5.  Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas.

Authors:  A Fazeli; R G Steen; S L Dickinson; D Bautista; W F Dietrich; R T Bronson; R S Bresalier; E S Lander; J Costa; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

Review 6.  The path to metastatic mouse models of colorectal cancer.

Authors:  Gabriele Romano; Sharmeen Chagani; Lawrence N Kwong
Journal:  Oncogene       Date:  2018-02-21       Impact factor: 9.867

7.  Reduction of pancreatic acinar cell tumor multiplicity in Dnmt1 hypomorphic mice.

Authors:  Shirley Oghamian; Nicole M Sodir; Muhammad U Bashir; Hui Shen; Andrea E Cullins; Cindy A Carroll; Pratima Kundu; Darryl Shibata; Peter W Laird
Journal:  Carcinogenesis       Date:  2011-03-01       Impact factor: 4.944

8.  The what, where, when and how of Wnt/β-catenin signaling in pancreas development.

Authors:  L Charles Murtaugh
Journal:  Organogenesis       Date:  2008-04       Impact factor: 2.500

9.  PUMA suppresses intestinal tumorigenesis in mice.

Authors:  Wei Qiu; Eleanor B Carson-Walter; Shih Fan Kuan; Lin Zhang; Jian Yu
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

10.  Genetic reconstitution of tumorigenesis in primary intestinal cells.

Authors:  Kunishige Onuma; Masako Ochiai; Kaoru Orihashi; Mami Takahashi; Toshio Imai; Hitoshi Nakagama; Yoshitaka Hippo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.